⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3894514 | 0.91 | — | — | |
| SCHEMBL3889626 | 0.91 | — | — | |
| SCHEMBL20585627 | 0.80 | — | — | |
| SCHEMBL1930146 | 0.67 | — | — | |
| SCHEMBL12054244 | 0.67 | — | — | |
| SCHEMBL15459919 | 0.63 | — | — | |
| Phosphine SCHEMBL15477090 | 0.60 | — | — | |
| SCHEMBL10519988 | 0.60 | — | — | |
| SCHEMBL5609754 | 0.60 | — | — | |
| SCHEMBL7747559 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119255997-A | Modulators of c-MYC mRNA translation and their use in the treatment of cancer | 艾尼莫生物科技公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-118108700-A | Complement factor B inhibitor, pharmaceutical composition, preparation method and application thereof | 诺华股份有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-117756698-A | Urea compound and medical application thereof as STING inhibitor | 中国药科大学 | 2024-03-26 | — | — | CN | disclosed |
| CN-117120051-A | Thyroid hormone receptor beta agonist compounds | 拓臻制药公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-114173772-A | Inhibitors of CD40-CD154 binding | 托尼克斯医药控股公司 | 2022-03-11 | — | — | CN | disclosed |
| US-10981888-B2 | Preparation method for tricyclic compounds | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2021-04-20 | — | — | US | disclosed |
| US-20190315707-A1 | PREPARATION METHOD FOR TRICYCLIC COMPOUNDS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2019-10-17 | — | — | US | disclosed |
| US-20160272600-A1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, LLC | 2016-09-22 | — | — | US | disclosed |
| US-9212153-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-8921359-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140200223-A1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. | 2014-07-17 | — | — | US | disclosed |
| US-8633212-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-8293923-B2 | Indazole derivatives as modulators of interleukin-1 receptor-associated kinase | BIOGEN IDEC MA INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20110152260-A1 | Indazole derivatives as modulators of interleukin-1 receptor-associated kinase | BIOGEN IDEC MA INC. (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110071126-A1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |